

Maternal Immunization Effectiveness Against Pertussis

4th Dec 2021 (Sat) | 4:00 pm — 5:30 pm



Agenda

Time	Agenda	Speakers
4:00 pm – 4:05 pm	Opening	Soon Yu-Wen <i>Medical Advisor GSK Vaccines Malaysia</i>
4:05 pm – 4:35 pm	Role of Maternal Pertussis Immunisation to Protect Newborn	Dr Yap Moy Juan <i>Consultant Obstetrician & Gynaecologist, Fetal Medicine & Gynaecology Centre, PJ</i>
4:35 pm – 5:05 pm	Does Tdap in MI prevent Neonatal Pertussis?: A Highlight of Real World Evidence	Dr Olakunle Oladehin <i>Area Medical Lead Growth Emerging Markets, GSK Vaccines</i>
5:05 pm – 5:25 pm	Q&A	All
5:25 pm – 5:30 pm	Closing	Soon Yu-Wen



Scan QR code or Click Here to Register

Speakers



Soon Yu-Wen
Medical Advisor
GSK Vaccines Malaysia

Soon Yu-Wen is a Medical Advisor at GlaxoSmithKline Pharmaceutical Sdn Bhd. He is a Bachelor of Pharmacy Graduate from Monash University Malaysia. He served as a community pharmacist for 3 years before venturing out as a Medical Writer for 2 years.

Prior to his current appointment as Medical Advisor in GSK Vaccines, Yu-Wen has 3 years of experience in the field of Medical Affairs, responsible for furthering scientific discussions in the field of Vaccines, Consumer Healthcare, Respiratory, Psychiatry, Gynaecology, and Health Economics.



Dr Yap Moy Juan
Consultant Obstetrician & Gynaecologist,
Fetal Medicine & Gynaecology Centre, PJ

Dr Yap is qualified as an Obstetrician and Gynaecologist from the Royal College of Obstetrician and Gynaecologist (RCOG), United Kingdom in the year 2002. Trained at Manipal Academy of Higher Education as an undergraduate and subsequently at Hospital Seremban as house officer, medical officer as well as a Registrar and Clinical Specialist in the Department of Obstetrics and Gynaecology in the early years of service.

She has been practicing in the field of Fetal-Medicine at Fetal Medicine and Gynaecology Centre at Petaling Jaya, Malaysia since 2005.



Dr Olakunle Oladehin
Area Medical Lead
Growth Emerging Markets, GSK Vaccines

Dr Oladehin joined GSK in 2008 as Area Director, Clinical R&D, and Medical affairs (Sub Saharan Africa), and was responsible in supporting the life cycle of GSK vaccine in SSA, all through the clinical development and the eventual implementation of such vaccines in the national calendars of African countries. He has worked on the clinical development of vaccines such as rotavirus, HPV and pneumococcal vaccines, pioneered several vaccines advisory boards in Africa, with notable achievements supporting medical experts to make vaccine recommendations at country and regional level. He gained his medical degree from the Lagos University Teaching Hospital (LUTH) in 1998, where he developed keen interest in clinical research, ethics and good clinical practice. He has worked in various capacities as a clinician both at the private and public health facilities in Nigeria.

For Medical/Healthcare Professionals Only
Adverse events should be reported to drugsafetyinfo.my@gsk.com
Trade marks are owned by or licensed to the GSK group of companies
© 2021 GSK group of companies or its licensor



GlaxoSmithKline Pharmaceutical Sdn Bhd (Co. No.3277-U)
Level 6, Quill 9, 112, Jalan Professor Khoo Kay Kim,
46300 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: (603) 7495 2600 www.my.gsk.com